Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 2 | 2010 | 101 | 0.660 |
Why?
|
| Kidney Neoplasms | 2 | 2010 | 173 | 0.620 |
Why?
|
| Glomerulonephritis, Membranous | 3 | 2020 | 27 | 0.520 |
Why?
|
| Diabetic Nephropathies | 1 | 2013 | 61 | 0.420 |
Why?
|
| Kidney | 2 | 2013 | 677 | 0.380 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2010 | 8 | 0.370 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2010 | 5 | 0.360 |
Why?
|
| PAX2 Transcription Factor | 1 | 2010 | 22 | 0.360 |
Why?
|
| Podocytes | 1 | 2010 | 19 | 0.360 |
Why?
|
| Carcinoma, Papillary | 1 | 2010 | 49 | 0.350 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 68 | 0.350 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2010 | 78 | 0.340 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 281 | 0.340 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 183 | 0.320 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 153 | 0.320 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2010 | 182 | 0.310 |
Why?
|
| Heart Diseases | 1 | 2010 | 211 | 0.300 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 973 | 0.290 |
Why?
|
| Colorectal Neoplasms | 1 | 2010 | 255 | 0.280 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 402 | 0.260 |
Why?
|
| Kidney Diseases | 2 | 2019 | 212 | 0.240 |
Why?
|
| Lupus Nephritis | 1 | 2020 | 17 | 0.180 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 68 | 0.170 |
Why?
|
| Biopsy | 2 | 2013 | 592 | 0.170 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 14 | 0.170 |
Why?
|
| Humans | 13 | 2020 | 50201 | 0.130 |
Why?
|
| Proflavine | 1 | 2015 | 1 | 0.130 |
Why?
|
| Endothelin-1 | 1 | 2015 | 31 | 0.120 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 105 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 56 | 0.120 |
Why?
|
| Phenazopyridine | 1 | 2014 | 3 | 0.120 |
Why?
|
| Nephritis, Interstitial | 1 | 2014 | 9 | 0.110 |
Why?
|
| Contrast Media | 1 | 2015 | 186 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 111 | 0.110 |
Why?
|
| Myocardium | 1 | 2015 | 443 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2010 | 13 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2010 | 75 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 158 | 0.090 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2010 | 11 | 0.090 |
Why?
|
| Proteinuria | 1 | 2010 | 39 | 0.090 |
Why?
|
| Hematuria | 1 | 2010 | 26 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 112 | 0.090 |
Why?
|
| Fibroblast Growth Factors | 1 | 2010 | 44 | 0.090 |
Why?
|
| Neoplasms | 1 | 2020 | 1233 | 0.090 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2010 | 8 | 0.090 |
Why?
|
| Patents as Topic | 1 | 2010 | 9 | 0.090 |
Why?
|
| Female | 5 | 2019 | 26829 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 964 | 0.090 |
Why?
|
| Integrins | 1 | 2010 | 30 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 176 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2010 | 186 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2010 | 146 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 235 | 0.090 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 47 | 0.080 |
Why?
|
| Amlodipine | 1 | 2009 | 14 | 0.080 |
Why?
|
| Aging | 1 | 2015 | 674 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2010 | 108 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2010 | 117 | 0.080 |
Why?
|
| Fluorobenzenes | 1 | 2009 | 21 | 0.080 |
Why?
|
| Cardiomegaly | 1 | 2009 | 39 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 77 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 179 | 0.080 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 36 | 0.080 |
Why?
|
| Immunoglobulin G | 2 | 2020 | 184 | 0.080 |
Why?
|
| Calcium Channel Blockers | 1 | 2009 | 64 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 139 | 0.080 |
Why?
|
| Male | 6 | 2020 | 25572 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2009 | 125 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 871 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 137 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2009 | 192 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 144 | 0.080 |
Why?
|
| Nanoparticles | 1 | 2010 | 151 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 921 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1041 | 0.070 |
Why?
|
| Aged | 3 | 2020 | 9505 | 0.070 |
Why?
|
| Models, Biological | 1 | 2010 | 722 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 459 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2013 | 6190 | 0.050 |
Why?
|
| Middle Aged | 2 | 2013 | 12356 | 0.050 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2020 | 9 | 0.050 |
Why?
|
| Thrombospondins | 1 | 2020 | 8 | 0.050 |
Why?
|
| Receptors, Phospholipase A2 | 1 | 2020 | 14 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2020 | 54 | 0.040 |
Why?
|
| Autoantigens | 1 | 2020 | 50 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2020 | 114 | 0.040 |
Why?
|
| Kidney Glomerulus | 1 | 2019 | 39 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2012 | 2934 | 0.040 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2015 | 16 | 0.030 |
Why?
|
| beta-Galactosidase | 1 | 2015 | 35 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 106 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 2015 | 69 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 164 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 86 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 270 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 178 | 0.030 |
Why?
|
| Fibrosis | 1 | 2015 | 178 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 446 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2015 | 352 | 0.030 |
Why?
|
| Mice | 2 | 2015 | 5673 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 195 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 1390 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 2009 | 19 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 2009 | 67 | 0.020 |
Why?
|
| Lipids | 1 | 2009 | 147 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 382 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 579 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 1612 | 0.020 |
Why?
|
| Body Weight | 1 | 2009 | 513 | 0.020 |
Why?
|
| Animals | 2 | 2015 | 13141 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 556 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 612 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2009 | 527 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2009 | 840 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1000 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 1419 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2009 | 5203 | 0.010 |
Why?
|